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ABSTRACT
Objectives: There is evidence to suggest that noncompliant and nonper-
sistent behaviors have differing risk factors, clinical consequences, and
responses to intervention. This has led to calls for these behaviors to be
deﬁned and measured separately to characterize medication-taking behav-
ior comprehensively. Current prescription reﬁll models of compliance are,
however, unable to appropriately distinguish between noncompliant and
nonpersistent behaviors. To address this limitation, a prescription reﬁll
model of medication-taking behavior in which noncompliance and non-
persistence are treated as competing risks is presented.
Methods: The proposed competing risks model of compliance and persis-
tence is compared with a selection of widely applied prescription reﬁll
models of compliance and persistence using a common cohort of patients
prescribed statin therapy.
Results: The competing risks model allows the simultaneous measurement
of noncompliance and nonpersistence, the partitioning of their individual
contributions to medication-taking behavior, and the estimation of non-
compliance risk for patients with varying treatment persistence. The
results from this model provide information about the relative and overall
contributions of noncompliant and nonpersistent behaviors to medication-
taking behavior. The methodology also allows an assessment of the dif-
ferential inﬂuence of various risk factors on these behaviors.
Conclusions: The proposed competing risks model differentiates between
noncompliant and nonpersistent behaviors using prescription reﬁll data.
Results from the model provide insights into the dynamics of noncompli-
ant and nonpersistent behaviors that have not been possible with current
prescription reﬁll methodologies.
Keywords: competing risks, compliance, persistence, prescription reﬁll,
statins.
Introduction
Medication taking can be deﬁned in terms of two distinct behav-
iors: the length of time from initiation to discontinuation of
treatment—persistence; and the quality of treatment execution
during that time—compliance [1–3]. This distinction between
compliance and persistence implies that the quality of a patient’s
treatment execution can only be evaluated with respect to the
length of time that he/she is actively engaged in taking treatment
[1]. The extent to which a patient would act in accordance with
the prescribed interval and dosage of a treatment regimen cannot
be measured after that treatment has been discontinued and
periods of treatment nonpersistence should not therefore be con-
sidered part of a patient’s compliance behavior. The partitioning
of medication taking into compliance and persistence is sup-
ported by evidence indicating that the risk factors [4] and clinical
consequences [5,6] of the two behaviors differ. There is also
evidence to suggest that interventions to improve medication-
taking behavior can have a differing impact on compliance and
persistence [7]. These characteristics have led to the recommen-
dation that compliance and persistence should be deﬁned and
measured separately [1,8–10].
Prescription reﬁll records are an invaluable resource for the
assessment of medication-taking behaviors in large numbers of
patients over extended periods of time. The use and validity of
prescription reﬁll records for the measurement of compliance
have, however, been the subject of a number of recent criticisms
[11,12]. The most signiﬁcant of these is the contention that
prescription reﬁll records are unsuitable for the measurement of
compliance because they are unable to provide the necessary
distinction between noncompliant and nonpersistent behaviors.
These criticisms are based upon the observation that current
prescription reﬁll models of compliance allow the inclusion of
periods of treatment nonpersistence in their estimates of compli-
ant behavior [13–15]. This results in the underestimation of
compliance for nonpersistent patients and has led to the belief
that compliance with many treatments is as low as 50% to 60%
[16]. In addition, as compliance rates are underestimated speciﬁ-
cally for nonpersistent patients, estimates of noncompliance risk
obtained from these prescription reﬁll models are biased for
covariates associated with nonpersistence risk [14,15].
The evaluation of compliance behavior with respect to the
length of time that a patient persists with treatment is difﬁcult
with current compliance models because they are unable to
adequately account for the dependent nature of noncompliant
and nonpersistent behaviors and the systematic variations in
treatment duration this produces. To address these limitations,
this article presents a prescription reﬁll model of medication-
taking behavior in which established measures of noncompliance
and nonpersistence are modeled as competing risks. The use of a
competing risks model is appropriate in situations where more
than one type of event plays a role in failure and these events are
not independent, i.e., the occurrence of one event either precludes
or signiﬁcantly alters the probability of the other [17]. This
applies to the medication-taking process, where patients taking a
treatment are at simultaneous risk of both nonpersistence and
noncompliance; with the occurrence of either behavior signifying
a failure to take the treatment correctly although, respectively,
precluding or modifying the risk of the competing behavior.
Nonpersistence precludes the subsequent occurrence of noncom-
pliance, because it is not possible for a patient to exhibit non-
compliant behavior with a treatment he/she is no longer taking
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[1], whereas noncompliance increases the probability that a
patient will subsequently become nonpersistent [12]. The pro-
posed competing risks model appropriately accounts for the
dependence between noncompliant and nonpersistent behaviors
by changing the focus of analysis away from making inferences
about the risk of noncompliance occurring in patients who are
compliant, toward making inferences about the risk of noncom-
pliance occurring in patients who are both compliant and persis-
tent [17]. To illustrate this, the competing risks model is
compared with a number of commonly applied prescription reﬁll
models of compliance and persistence, using a cohort of patients
prescribed statin therapy.
Methods
Source of Data
Prescription reﬁll data was obtained from the Irish Health Care
Executive, Primary Care Reimbursement Services (HSE-PCRS)
database. This database records information on prescriptions
dispensed to patients with eligibility for the General Medical
Services (GMS) health-care scheme. The GMS provides free
health-care services, including the provision of medicines, to
patients over the age of 70 and patients who are unable without
undue hardship to arrange primary health-care services.
Approximately one-third (1.27 million) of the Irish population
were registered for this scheme in 2007.
Study Cohort and Covariates
All patients over the age of 16, commencing a statin (simvastatin,
pravastatin, ﬂuvastatin, atorvastatin, rosuvastatin, combined
simvastatin/ezetimibe) as initial antihyperlipidemic treatment
between the January 1, 2004 and January 2, 2006 were identiﬁed
from the HSE-PCRS database. The date of the ﬁrst prescription
for a statin during this period was identiﬁed as the index date for
each patient. Commencing statin treatment was deﬁned as
having no statin prescribed in the 365 days before the index date.
Initial treatment with a statin was deﬁned as having no other
antihyperlipidemic treatment prescribed in the 365 days before
the index date. Prescription reﬁll data were available from
January 1, 2003 to June 30, 2007. Information on loss of eligi-
bility for the GMS scheme or death was not available and
patients were instead considered lost to follow-up from the date
they received their last prescription for any type of medication.
A longitudinal data set of statin prescription reﬁlls was
assembled for each patient in the study cohort by assigning the
days’ supply from each prescription to sequential days from the
date of dispensing [18]. Prescriptions reﬁlled before the assigned
daily supply from previous prescriptions being exhausted were
handled in the following way: where an overlapping prescription
was for the same statin type, the days’ supply was appended to
the last assigned day of the previous prescription; where the
overlapping prescription was for a different statin type, indicat-
ing a treatment switch, the days’ supply remaining from previous
prescriptions was discarded. These longitudinal prescription reﬁll
histories were used in all of the compliance and persistence
models described next.
Covariates previously associated with statin noncompliance
were selected for inclusion in the prescription reﬁll models. These
included gender, age, statin type, and initial prescriber of current
statin (community or hospital). The presence of certain comor-
bidities was also identiﬁed using the prescription of speciﬁc drugs
as a surrogate marker for disease. Ischemic heart disease (IHD)
was identiﬁed by the presence of a prescription for a nitrate [19]
or potassium channel activator. Diabetes was identiﬁed by the
presence of a prescription for an oral antidiabetic medication or
insulin. Diagnoses of depression or Alzheimer’s disease were
identiﬁed by the presence of a prescription for an antidepressant
or anti-Alzheimer medication, respectively.
Standard Models of Compliance and Persistence
Three types of compliance model, commonly applied to prescrip-
tion reﬁll data, were identiﬁed from the literature. There has been
no published taxonomy of these models and they are referred to
here according to their general properties as single measure,
repeated measure, and time to noncompliance models.
Medication-taking behavior analyses based on the calculation
of a single measure of compliance over a speciﬁed observation
period are the most frequently utilized models for the assessment
of compliance with prescription reﬁll data [13,20]. A variety of
techniques have been proposed for the measurement of compli-
ance in these single measure models [20]. The medication pos-
session ratio (MPR) technique, recommended in the reviews by
Halpern et al. and Peterson et al. was used in this model [9,14].
Compliance rates were calculated for the single measure model
by dividing the number of days between the start of a patient’s
ﬁrst and last prescription reﬁlls, up to a maximum of 720 days,
into the number of daily doses assigned to that treatment inter-
val. The MPR technique cannot be used to calculate compliance
rates for patients receiving fewer than two prescriptions and
these patients were excluded from the single measure model.
Patients were deﬁned as noncompliant in the single measure
model if they had a compliance rate of less than 80%.
Repeated measure models of compliance are based upon the
periodic calculation of a patient’s compliance over consecutive
intervals of a deﬁned length [14]. A variety of interval lengths has
been used in the past with little objective rationale given for their
selection [18,21–25]. The most frequently used interval length of
90 days was selected for use in this model. This represents three
times the average length of a statin prescription in the HSE-PCRS
database. Compliance rates were calculated for each complete
consecutive 90-day interval in a patient’s follow-up by dividing
the number of daily doses assigned to each interval by 90. Com-
pliance rates could not be calculated for patients with less than
90 days’ follow-up and these patients were excluded from the
repeated measure model. Patients were deﬁned as noncompliant
in any given 90-day interval if they had a compliance rate of less
than 80% for that interval.
Time to noncompliance models provide an estimation of the
length of time a patient can be expected to take a medication at
or above a certain intensity [26–28]; where the intensity can be
deﬁned in terms of both the level of noncompliance and the
length of the noncompliant episode. In this study, compliance
rates were calculated for every day in a patient’s follow-up by
dividing the number of days between treatment initiation and
each day, into the number of daily doses assigned to that treat-
ment interval. For example: a patient’s compliance rate at day 40
was calculated by dividing the number of days from treatment
initiation into the number of doses assigned to that 40-day treat-
ment interval. This calculation was repeated for every day in a
patient’s follow-up. Patients were deﬁned as noncompliant if
their compliance rate dropped below 80% for at least 180 con-
secutive days. The time to noncompliance was deﬁned as the
length of time from treatment initiation to the ﬁrst day of this
noncompliant episode. Patients who became lost to follow-up
during the deﬁned noncompliant episode length were identiﬁed
as lost to follow-up instead.
Persistence with statin therapy was also measured using a
standard permissible gap model [13]. Patients were identiﬁed as
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nonpersistent if the number of consecutive days without an
assigned statin dose exceeded a permissible gap of 180 days. The
time to nonpersistence was taken as the length of time from
treatment initiation to the ﬁrst day of the deﬁned permissible gap.
Patients who became lost to follow-up during the deﬁned non-
persistent episode length were identiﬁed as lost to follow-up
instead.
Competing Risks Model of Compliance and Persistence
In the competing risks model of medication-taking behavior,
noncompliance and nonpersistence are treated as separate events,
with the earliest occurrence of either identiﬁed as the deﬁning
event for each patient. This approach ensures that only noncom-
pliant events occurring during the time that a patient persists
with treatment are considered part of a patient’s compliance
behavior. For this study, time to noncompliance and time to
nonpersistence were measured using the standard deﬁnitions and
established techniques described previously. Noncompliant
events were deﬁned as a compliance rate of less than 80% for at
least 180 consecutive days. Nonpersistent events were deﬁned as
a permissible gap in treatment of at least 180 consecutive days.
Patients who became nonpersistent during the deﬁned 180-day
noncompliance episode were identiﬁed as nonpersistent instead
(i.e., for a patient to be considered noncompliant, his/her com-
pliance rate must have dropped below 80% for 180 consecutive
days, but he/she could not become nonpersistent during this
180-day period).
In addition to modeling noncompliance and nonpersistence
as separate competing risks, these two events were combined into
a single composite outcome to allow assessment of their joint
contribution to medication-taking behavior. In this composite
model, the time to either noncompliance or nonpersistence, as
identiﬁed in the competing risks model described previously, was
taken as the time to event for each patient.
Sensitivity Analyses
A sensitivity analysis was undertaken to conﬁrm the robustness
of the competing risks model to variations in the permissible gap
length (90 days and 360 days). The single measure model of
compliance was also repeated with the more commonly used,
shorter maximum patient follow-up of 360 days.
Statistical Analysis
Compliance rates from the single measure model were dichoto-
mized into compliant (80%) or noncompliant (<80%). A mul-
tiple logistic regression analysis was used to estimate
noncompliance odds ratios with 95% conﬁdence intervals for
each covariate. Compliance rates from the repeated measure
model were also dichotomized into compliant (80%) and non-
compliant (<80%). A multivariate generalized estimating equa-
tion (GEE) model with a binomial variance distribution, a
common logit link function, and an unstructured correlation
matrix was used to estimate noncompliance odds ratios with
95% conﬁdence intervals for each covariate. Results from the
time to noncompliance model, the time to nonpersistence model,
and the composite competing risks model were analyzed as
follows. A Kaplan–Meier plot was constructed to estimate the
cumulative probability of an event and a multiple Cox regression
model was used to estimate hazard ratios with 95% conﬁdence
intervals for covariates in each model. Observations were cen-
sored at the time of an event, loss to follow-up or end of follow-
up, whichever occurred ﬁrst. Where possible covariates were
treated as time-varying in analyses, otherwise baseline values at
treatment initiation were used.
Cumulative incidence functions [29] for the individual com-
peting risks of noncompliance and nonpersistence were estimated
using the SAS® macro incid. [30] Observations were censored at
loss to follow-up or end of follow-up, whichever occurred ﬁrst.
Multiple regression models based on the competing risk cumu-
lative incidence functions were constructed using the pseudo-
value approach developed by Andersen, Klein and Rosthøj
[31,32]. This technique allows the direct regression modeling of
the cumulative incidence function using pseudo-values based on
the difference between the complete sample and the “leave-one-
out” estimators of relevant survival quantities (jack-knife proce-
dure) [32]. The pseudo-values for the competing risks cumulative
incidence functions were calculated using the SAS macros
pseudoci [33] and cuminc [33]. To accommodate the large
sample size, only data relevant to the individual jack-knife pro-
cedure were derived at each iteration. Time-dependent covariates
were incorporated into the model by prespecifying a series of
time points for the calculation of corresponding pseudo-values
[32,34]. The calculated pseudo-values were used as the depen-
dent variable in GEE regression analyses for the competing risks.
The distribution for these GEE models was speciﬁed as normal,
the link function was the complementary log–log function,
and the correlation structure was speciﬁed as independent
[32,35]. The complementary log–log function gives a propor-
tional hazards representation when applied to a survival function
[35,36], allowing the exponentiated b regression coefﬁcients
from the GEE model to be interpreted as hazard ratios with 95%
conﬁdence intervals, or more appropriately as sub-distribution
hazard ratios [36]. Detailed descriptions of the pseudo-value
methodology and guides to the application of the SAS macros
have been published by Klein et al. [32,35], Anderson et al. [31]
and Rosthøj et al. [37]. SAS versions 9.1.2 and 9.2 (SAS Institute,
Cary, NC) were used for all analyses and signiﬁcance at P < 0.05
was assumed.
Results
Study Cohort
A cohort of 79,364 patients aged 16 years or older, commencing
a statin as initial antihyperlipidemic treatment was identiﬁed (see
Table 1). Females accounted for 55.6% of the study cohort and
62.5% of patients were aged 65 years or over at treatment
initiation. Atorvastatin represented 60.3% of initial prescrip-
tions, with 16% of patients receiving two or more different
statins. The proportion of patients excluded from the single
measure and repeated measure compliance models because of
insufﬁcient prescription reﬁlls or follow-up was 11.4% and
4.1%, respectively. The characteristics of these abridged cohorts
are also presented.
Noncompliance and Nonpersistence Models
A selection of noncompliance and nonpersistence estimates from
the competing risks and standard prescription reﬁll models are
presented in Table 2. Cumulative incidence plots for the indi-
vidual and composite competing risks models are also shown in
Figure 1. As expected, the separation of noncompliant and non-
persistent behaviors in the competing risks model produces non-
compliance rate estimates that are considerably lower than those
obtained from the three standard models of noncompliance. At
720 days’ poststatin, initiation the proportion of patients iden-
tiﬁed as noncompliant in the competing risks model was 24.7%
versus 37.6%, 47.3% and 52.6% in the single measure, repeated
measure, and time to noncompliance models, respectively.
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Results from the multiple regression analyses for the compet-
ing risks and standard prescription reﬁll models are presented in
Table 3. A comparison of these results reveals that noncompli-
ance risk estimates for a number of covariates, e.g., age, statin
type and certain comorbidities, differ substantially between the
competing risks and standard compliance models. In the three
standard compliance models, noncompliance risk decreased with
increasing age and there was a reduced risk of noncompliance in
patients treated for IHD or diabetes. Noncompliance risk was
also lower in patients prescribed atorvastatin, rosuvastatin, or
the simvastatin/ezetimibe combination; whereas the use of ﬂuv-
astatin was associated with an increased risk of noncompliance.
These risk estimates are similar to those observed in previously
published prescription reﬁll studies of statin compliance
[22,23,38]. In the competing risks model, however, noncompli-
ance risk increased with age up to the 45–54 years age category,
decreasing thereafter. Treatment for IHD or diabetes was associ-
ated with little or no reduction in the risk of noncompliance
and there was no difference in noncompliance risk between
statin types, with the exception of the simvastatin/ezetimibe
combination.
In comparison to the standard permissible gap model of
nonpersistence, the proportion of patients identiﬁed as nonper-
sistent and the distribution of nonpersistence risk remained
largely unchanged in the competing risks model (see Tables 2 and
3). At 720 days after treatment initiation, 28.3% of patients were
identiﬁed as nonpersistent in the competing risks model versus
32.6% in the standard permissible gap model. Increasing age, the
presence of ischemic heart disease or diabetes, the use of atorv-
astatin or rosuvastatin, and the initiation of treatment by a
hospital prescriber remained signiﬁcant predictors of persistence.
It is also interesting to note that the covariate risk estimates for
the composite outcome of noncompliance/nonpersistence in the
competing risks model are remarkably similar to those obtained
from the three standard models of compliance.
Sensitivity Analyses
Cumulative incidence and covariate risk estimates from sensitiv-
ity analyses assessing the inﬂuence of permissible gap length on
the competing risks model are presented in Tables A1 and A2,
respectively (see appendix at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH13i6_Barron.asp). Varying the
length of permissible gap between 90 and 360 days changed the
relative proportion of noncompliant and nonpersistent events
but had little effect on the number of composite events (noncom-
pliance and nonpersistence). This is because patients were in
general reclassiﬁed from nonpersistent to noncompliant or vice
versa as the permissible gap length increased or decreased.
Despite these variations in the proportions of noncompliant and
nonpersistent events, there was minimal change in covariate risk
estimates, suggesting that the competing risks model is robust to
variations in the permissible gap length used to deﬁne nonpersis-
tence. In the single measure model sensitivity analysis, the use of
a shorter maximum patient follow-up of 360 days produced little
variation in the noncompliance rate estimate or the covariate risk
estimates obtained.
Discussion
The competing risks model of medication-taking behavior pre-
sented in this article is the ﬁrst to differentiate between noncom-
pliant and nonpersistent behaviors using prescription reﬁll data.
The results provide important insights into the dynamics of these
behaviors that have not been possible with current prescription
reﬁll methodologies.
Table 1 Baseline characteristics of the full study cohort and the study cohort subsets used in single measure and repeated measure compliance models
Full cohort*† (%) Single measure model cohort‡ (%) Repeated measure model cohort§ (%)
N 79,364 — 70,351 — 76,119 —
Gender
Male 35,265 (44.4) 31,137 (44.3) 33,646 (44.2)
Female 44,099 (55.6) 39,214 (55.8) 42,473 (55.8)
Age
16–34 2,666 (3.4) 1,260 (1.8) 2,118 (2.8)
35–44 3,676 (4.6) 2,776 (3.9) 3,384 (4.4)
45–54 8,576 (10.8) 7,459 (10.6) 8,199 (10.8)
55–64 14,864 (18.7) 13,615 (19.4) 14,424 (18.9)
65–74 25,382 (32.0) 23,580 (33.5) 24,821 (32.6)
75 24,200 (30.5) 21,661 (30.8) 23,173 (30.4)
Statin type
Simvastatin 4,553 (5.7) 3,954 (5.6) 4,336 (5.7)
Pravastatin 17,085 (21.5) 14,687 (20.9) 16,284 (21.4)
Fluvastatin 1,375 (1.7) 1,128 (1.6) 1,307 (1.7)
Atorvastatin 47,881 (60.3) 42,952 (61.1) 45,988 (60.4)
Rosuvastatin 8,145 (10.3) 7,344 (10.4) 7,891 (10.4)
Sim/Eze 325 (0.4) 286 (0.4) 313 (0.4)
Prescriber
Community 71,841 (90.5) 63,307 (90.0) 69,030 (90.7)
Hospital 7,523 (9.5) 7,044 (10.0) 7,089 (9.3)
Comorbidities
IHD 7,413 (9.3) 6,901 (9.8) 10,514 (13.8)
Diabetes 8,852 (10.8) 8,043 (11.4) 11,038 (14.5)
Depression 17,159 (21.6) 15,152 (21.5) 18,371 (24.1)
Alzheimer’s disease 1,117 (1.4) 963 (1.4) 1,476 (1.9)
*The full study cohort was not eligible for use in the single measure and repeated measure models.
†Baseline values at treatment initiation.
‡Baseline values at end of ﬁrst compliance calculation interval.
‡Single measure model of compliance estimated at 720 days follow-up or last statin prescription.
§Repeated measure model of compliance estimated over consecutive 90-day compliance calculation intervals.
IHD, ischemic heart disease; N, number of patients in cohort; Sim/Eze, simvastatin/ezetimibe combination.
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There are a number of considerations which must be taken
into account when interpreting results from the competing risks
model. Firstly, cumulative incidence estimates of noncompliance
are interpretable as the probability of a patient becoming non-
compliant at a speciﬁed time, given that the patient was both
compliant and persistent up to that time. The competing risks
regression estimates for noncompliance must consequently be
interpreted as part of an overall assessment of the relative and
combined contributions of noncompliance and nonpersistence to
medication-taking behavior. Secondly, the results reﬂect an
assessment of medication taking behavior within a single treat-
ment episode (initiation to nonpersistence). Thirdly the compet-
ing risks model makes no assumptions about the relationship,
i.e., independence, between noncompliant and nonpersistent
behaviors. It is therefore incorrect to assume that upon the
removal of one cause of failure, the risk of failure from other
causes will remain unchanged.
Results from the competing risks model indicate that non-
compliant behavior with statin therapy is not as prevalent as
previously suggested [22,23,38]. Noncompliance estimates from
the competing risks model are in fact comparable to those
obtained from studies using “gold standard” compliance mea-
surement techniques such as electronic medication event moni-
tors [39,40]. These studies have reported statin noncompliance
rates, exclusive of treatment nonpersistence, of 15.7% at 6
months. The cumulative incidence of noncompliance in the com-
peting risks model at 6 months was 18.3% (Table 2). Neverthe-
less, more than half (53.0%) of patients commenced on statin
therapy will have experienced either a noncompliant (24.7%) or
a nonpersistent (28.3%) event within 720 days of starting treat-
ment (see Table 2).
In comparison to regression estimates from the standard com-
pliance and persistence models, results from the competing risks
regression analyses allow a more detailed interpretation of the
differential inﬂuence of various risk factors on noncompliant and
nonpersistent behaviors. For example, results from the standard
compliance and persistence models demonstrate a reduced risk of
noncompliance and nonpersistence in patients receiving treat-
ment for diabetes. Nevertheless, the separation of nonpersistent
behavior from compliance estimates in the competing risks
model reveals that there is in fact no difference in compliance
behavior between patients with or without diabetes; although
patients with diabetes do have a reduced risk of nonpersistence
(see Table 3). Similar results are observed for statin type, where
regression estimates from the standard compliance models
suggest that there are considerable differences in compliance
behavior between a number of the statins. In contrast, results
from the competing risks model demonstrate that although there
are differences in persistence behavior between the various
statins, there is little difference in compliance behavior.
Regression estimates from the competing risks analyses
suggest that much of the reported variation in statin noncompli-
ance risk from standard compliance models is in fact attributable
to differences in persistence behavior. It is recognized that stan-
dard models of compliance that do not exclude periods of treat-
ment nonpersistence from compliance estimates can be thought
of as representing both noncompliant and nonpersistent behav-
iors in a single hybrid or composite estimate of medication-
taking behavior [14,15], with the risk assigned to covariates in
predictive models reﬂecting the combined risk for either of these
behaviors. This is conﬁrmed by the similarity between results
obtained from the three standard compliance models and the
composite noncompliance/nonpersistence competing risks model
(see Tables 2 and 3). Nevertheless, as demonstrated previously,
the appropriate interpretation of these composite medication-Ta
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taking behavior estimates is difﬁcult without knowledge of the
individual contributions of their component parts.
In addition to yielding information lacking from traditional
methods about the dynamics of medication-taking behaviors, the
competing risks model may also be of use in clinical practice.
Sensitivity analyses indicate that the use of permissible gaps as
short as 90 days to deﬁne nonpersistence is possible. This allows
the provision of timely data on medication-taking behavior to
guide the use of behavior-speciﬁc interventions. The ability to
distinguish between those who do not take their treatment cor-
rectly and those who do not take it at all, in conjunction with a
knowledge of the timing and speciﬁc risk factors for each behav-
ior, provides important information for the targeting and tailor-
ing of effective interventions [7]. Nonpersistent patients may
require interventions aimed at inﬂuencing their perceptions
about the risks and beneﬁts of treatment [41]; whereas, noncom-
pliant patients have at least acknowledged the need for treatment
and may instead require interventions aimed at facilitating the
integration of dosing into their daily routine [42,43]. It is also
worthwhile noting the timing of nonadherent and nonpersistent
events, the majority of which occur after the ﬁlling of a single
prescription or within the ﬁrst 90 days of treatment (see Fig. 1).
This suggests that interventions timed to coincide with the ini-
tiation of treatment and the following months may provide the
most beneﬁt.
Distinguishing between noncompliance and nonpersistence
also has implications for studies assessing the impact of
medication-taking behaviors on treatment outcomes. Studies of
“on treatment” efﬁcacy have generally concluded that statin
compliance rates of 80% are required for optimal outcomes
[44–49]. The majority of these studies do not, however, distin-
guish between noncompliant and nonpersistent behaviors in their
analyses. It is therefore possible that the level of statin compli-
ance necessary for optimal efﬁcacy is overestimated for patients
who are persistent with treatment. This observation is supported
by clinical trials indicating that statins have the ability to main-
tain efﬁcacy with alternate day, twice weekly, or even once
weekly dosing [6,50–53]; whereas periods of statin nonpersis-
tence of as little as 90 days can signiﬁcantly reduce treatment
efﬁcacy [5,54].
It is still possible and not incorrect to continue modeling
nonpersistent behavior using standard time to event models. The
competing risks model does, however, provide a different perspec-
tive on the analysis of persistence behavior by allowing the
assessment of nonpersistence risk speciﬁcally in patients who are
compliant with treatment. Nonpersistence models with similar
intent to this but different methodology have been published [12].
In these studies, noncompliance was included as a time-dependent
covariate in time to nonpersistence models, giving what can be
considered a bidirectional noncompliance/nonpersistence multi-
state model [17]. The advantage of this approach for the analysis
of nonpersistence is that it allows the assessment of nonpersistence
risk beyond the ﬁrst noncompliant episode.
In addition to the well-recognized limitations of retrospective
databases and prescription reﬁll data for the analysis of
medication-taking behavior [14,20,55], there are a number of
limitations speciﬁc to the competing risks model presented here.
Firstly, as the competing risks model makes no assumptions
about the correlation between noncompliant and nonpersistent
behaviors, the interpretation of covariate risk estimates from the
competing risks regression analyses requires some care. Secondly,
as with all prescription reﬁll models of medication-taking behav-
ior, the parameters selected to deﬁne noncompliant and nonper-
sistent behaviors have the potential to inﬂuence the results
obtained. In the competing risks model, the length of permissible
gap used to deﬁne nonpersistence simultaneously deﬁnes the
minimum gap between prescription reﬁlls that is considered non-
persistence and the maximum gap between prescription reﬁlls
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Figure 1 Competing risks cumulative incidence plot of statin noncompliance, statin nonpersistence, and composite statin noncompliance/nonpersistence.
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that is considered noncompliance. Although sensitivity analyses
indicate that the covariate risk estimates from the competing
risks model are robust to the speciﬁcation of a permissible gap
length, the relative proportion of noncompliant and nonpersis-
tent events does vary. Efforts should be made to select a permis-
sible gap length that reﬂects the minimum period of medication
disuse that distinguishes nonpersistent behavior (i.e., an intention
to discontinue treatment) from noncompliant behavior [9]. Sen-
sitivity analyses should also be carried out in situations where a
clinically appropriate compliance rate cutoff cannot be identiﬁed.
In conclusion, the competing risks model described in this
article addresses a number of the limitations of standard pre-
scription reﬁll compliance models by allowing the simultaneous
estimation of noncompliant and nonpersistent behaviors; the
partitioning of their individual contributions to medication
taking; and the appropriate estimation of noncompliance risk for
patients with varying treatment persistence. The results from this
model provide a more detailed description of the medication-
taking process in addition to allowing a comparison of the dif-
ferential inﬂuence of various risk factors on noncompliant and
nonpersistent behaviors.
Acknowledgments
This research and Dr T. Ian Barron’s position were supported by
the Irish Heart Foundation. This article is dedicated to the
memory of the late Professor John Feely.
Source of ﬁnancial support: This research and Dr. Barron’s position were
supported by the Irish Heart Foundation.
References
1 Cramer J, Roy A, Burrell A, et al. Medication compliance and
persistence: terminology and deﬁnitions. Value Health 2008;11:
44–7.
2 Osterberg L, Blaschke T. Adherence to medication. N Engl J Med
2005;353:487–97.
3 Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient
adherence to treatment: three decades of research. A comprehen-
sive review. J Clin Pharm Ther 2001;26:331–42.
4 Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the
immunomodulatory drugs for multiple sclerosis: contrasting
factors affect stopping drug and missing doses. Pharmacoepide-
miol Drug Saf 2008;17:565–76.
5 Daskalopoulou SS, Delaney JA, Filion KB, et al. Discontinuation
of statin therapy following an acute myocardial infarction: a
population-based study. Eur Heart J 2008;29:2083–91.
6 Metz CA, Lucas KH. Alternate-day dosing of HMG-CoA reduc-
tase inhibitors for cholesterol reduction. Ann Pharmacother
2001;35:496–500.
7 Vrijens B, Belmans A, Matthys K, et al. Effect of intervention
through a pharmaceutical care program on patient adherence
with prescribed once-daily atorvastatin. Pharmacoepidemiol
Drug Saf 2006;15:115–21.
8 Cramer J, Roy A, Burrell A, et al. Medication compliance and
persistence: terminology and deﬁnitions. Value Health 2007;11:
44–7.
9 Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for
evaluating compliance and persistence with hypertension therapy
using retrospective data. Hypertension 2006;47:1039–48.
10 Steiner JF, Gardner EM. Assessing medication adherence from
pharmacy records. Pharmacoepidemiol Drug Saf 2006;15:575–
77.
11 Urquhart J. Pharmionics: research on what patients do with pre-
scription drugs. Pharmacoepidemiol Drug Saf 2004;13:587–90.
12 Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed
antihypertensive drug treatments: longitudinal study of electroni-
cally compiled dosing histories. BMJ 2008;336:1114–17.
13 Andrade SE, Kahler KH, Frech F, Chan K. Methods for evalua-
tion of medication adherence and persistence using automated
databases. Pharmacoepidemiol Drug Saf 2006;15:565–74. Dis-
cussion 75–7.
14 Peterson AM, Nau DP, Cramer JA, et al. A checklist for medica-
tion compliance and persistence studies using retrospective data-
bases. Value Health 2007;10:3–12.
15 Schultz JS, O’Donnell JC, McDonough KL, et al. Determinants of
compliance with statin therapy and low-density lipoprotein cho-
lesterol goal attainment in a managed care population. Am J
Manag Care 2005;11:306–12.
16 Peterson AM, McGhan WF. Pharmacoeconomic impact of non-
compliance with statins. Pharmacoeconomics 2005;23:13–25.
17 Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: compet-
ing risks and multi-state models. Stat Med 2007;26:2389–430.
18 Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in
use of statin therapy in elderly patients. JAMA 2002;288:455–61.
19 Gray J, Majeed A, Kerry S, Rowlands G. Identifying patients with
ischaemic heart disease in general practice: cross sectional study
of paper and computerised medical records. BMJ 2000;321:548–
50.
20 Steiner JF, Prochazka AV. The assessment of reﬁll compliance
using pharmacy records: methods, validity, and applications. J
Clin Epidemiol 1997;50:105–16.
21 Benner JS, Pollack MF, Smith TW, et al. Association between
short-term effectiveness of statins and long-term adherence to
lipid-lowering therapy. Am J Health Syst Pharm 2005;62:1468–
75.
22 Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests
and physician visits are associated with improved adherence to
statin therapy. Pharmacoeconomics 2004;22(Suppl. 3):13–23.
23 Caspard H, Chan AK, Walker AM. Compliance with a statin
treatment in a usual-care setting: retrospective database analysis
over 3 years after treatment initiation in health maintenance
organization enrollees with dyslipidemia. Clin Ther 2005;27:
1639–46.
24 Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adher-
ence with antihypertensive and lipid-lowering therapy. Arch
Intern Med 2005;165:1147–52.
25 Gibson TB, Mark TL, McGuigan KA, et al. The effects of pre-
scription drug copayments on statin adherence. Am J Manag Care
2006;12:509–17.
26 Abraha I, Montedori A, Stracci F, et al. Statin compliance in the
Umbrian population. Eur J Clin Pharmacol 2003;59:659–61.
27 Lesaffre E, Kocmanova D, Lemos PA, et al. A retrospective analy-
sis of the effect of noncompliance on time to ﬁrst major adverse
cardiac event in LIPS. Clin Ther 2003;25:2431–47.
28 Clowes JA, Peel NF, Eastell R. The impact of monitoring on
adherence and persistence with antiresorptive treatment for post-
menopausal osteoporosis: a randomized controlled trial. J Clin
Endocrinol Metab 2004;89:1117–23.
29 Kim HT. Cumulative incidence in competing risks data and com-
peting risks regression analysis. Clin Cancer Res 2007;13:559–
65.
30 Medical College of Wisconsin GSoBS, Department of Population
Health, Division of Biostatistics. SAS Macro for cumulative inci-
dence functions.
31 Andersen PK, Klein JP, Rosthøj S. Generalised linear models for
correlated pseudo-observations, with applications to multi-state
models. Biometrika 2003;90:15–27.
32 Klein JP, Gerster M, Andersen PK, et al. SAS and R functions to
compute pseudo-values for censored data regression. Comput
Methods Programs Biomed 2008;89:289–300.
33 Medical College of Wisconsin GSoBS, Department of Population
Health, Division of Biostatistics. SAS Macros to ﬁnd pseudo-
values for censored data.
34 Logan BR, Klein JP, Zhang MJ. Comparing treatments in the
presence of crossing survival curves: an application to bone
marrow transplantation. Biometrics 2008;64:733–40.
35 Klein JP, Andersen PK. Regression modeling of competing risks
data based on pseudovalues of the cumulative incidence function.
Biometrics 2005;61:223–9.
Competing Risks Model of Compliance 803
36 Ambrogi F, Biganzoli E, Boracchi P. Clinical useful measures for
the study of competing risks in survival analysis. 28th Annual
Conference of the International Society for Clinical Biostatistics.
Alexandropoulis, Greece, 2007.
37 Rosthøj S, Andersen PK, Abildstrom SZ. SAS macros for estima-
tion of the cumulative incidence functions based on a Cox regres-
sion model for competing risks survival data. Comput Methods
Programs Biomed 2004;74:69–75.
38 LaFleur J, Thompson CJ, Joish VN, et al. Adherence and persis-
tence with single-dosage form extended-release niacin/lovastatin
compared with statins alone or in combination with extended-
release niacin. Ann Pharmacother 2006;40:1274–9.
39 Cheng CW, Woo KS, Chan JC, et al. Assessing adherence to statin
therapy using patient report, pill count, and an electronic moni-
toring device. Am J Health Syst Pharm 2005;62:411–15.
40 Cheng CW, Woo KS, Chan JC, et al. Association between adher-
ence to statin therapy and lipid control in Hong Kong Chinese
patients at high risk of coronary heart disease. Br J Clin Pharma-
col 2004;58:528–35.
41 McGinnis B, Olson KL, Magid D, et al. Factors related to adher-
ence to statin therapy. Ann Pharmacother 2007;41:1805–11.
42 Rosen MI, Rigsby MO, Salahi JT, et al. Electronic monitoring
and counseling to improve medication adherence. Behav Res Ther
2004;42:409–22.
43 Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with
monetary reinforcement: pilot study of an antiretroviral adher-
ence intervention. J Gen Intern Med 2000;15:841–7.
44 Compliance and adverse event withdrawal: their impact on the
West of Scotland Coronary Prevention Study. Eur Heart J
1997;18:1718–24.
45 Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to
statins on coronary artery disease in primary prevention. Br J Clin
Pharmacol 2007;63:698–708.
46 Perreault S, Dragomir A, Blais L, et al. Impact of adherence to
statins on chronic heart failure in primary prevention. Br J Clin
Pharmacol 2008;66:706–16.
47 Wei L, Fahey T, MacDonald TM. Adherence to statin or aspirin
or both in patients with established cardiovascular disease:
exploring healthy behaviour vs. drug effects and 10-year
follow-up of outcome. Br J Clin Pharmacol 2008;66:110–16.
48 Wei L, Wang J, Thompson P, et al. Adherence to statin treatment
and readmission of patients after myocardial infarction: a six year
follow up study. Heart 2002;88:229–33.
49 Valuck RJ, Williams SA, MacArthur M, et al. A retrospective
cohort study of correlates of response to pharmacologic therapy
for hyperlipidemia in members of a managed care organization.
Clin Ther 2003;25:2936–57.
50 Hughes DA, Walley T. Predicting “real world” effectiveness by
integrating adherence with pharmacodynamic modeling. Clin
Pharmacol Ther 2003;74:1–8.
51 Stern RH, Abel RB. Rate of low-density lipoprotein cholesterol
and apolipoprotein B changes on initiation and discontinuation of
atorvastatin treatment. J Clin Pharmacol 1997;37:291–6.
52 Sampietro T, Galetta F, Bionda A. Behavior of Lp(a) and apo-
proteins (A1, B, C2, C3, E) during and after therapy with simv-
astatin. Cardiovasc Drugs Ther 1995;9:785–9.
53 Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose
of atorvastatin effective in treating patients with hyperlipidemia?
The Alternate Day Versus Daily Dosing of Atorvastatin Study
(ADDAS). Am Heart J 2002;144:674–7.
54 Colivicchi F, Bassi A, Santini M, et al. Discontinuation of statin
therapy and clinical outcome after ischemic stroke. Stroke
2007;38:2652–7.
55 Motheral B, Brooks J, Clark MA, Caltagirone C. A checklist for
retrospective database studies—report of the ISPOR Task Force
on Retrospective Databases. Value Health 2003;6:90–7.
804 Barron et al.
